Chronic Inflammation via suPAR: The Missing Link Between Diabetes and Cardiovascular Mortality

MedXY Editorial Team•Mar 14, 2026•Cardiology

Soluble urokinase plasminogen activator receptor (suPAR) levels are significantly higher in patients with Type 2 Diabetes (T2D) compared to those without.
In patients with Coronary Artery Disease (CAD), suPAR mediates more than 50% of the association between T2D and adverse outcomes, including cardiovascular death and myocardial infarction.
Unlike high-sensitivity C-reactive protein (hs-CRP), suPAR acts as a critical independent mediator of the diabetic cardiovascular risk profile.
These findings suggest that chronic immune activation, rather than just acute-phase inflammation, drives the poor prognosis seen in diabetic patients with heart disease.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Soluble urokinase plasminogen activator receptor (suPAR) levels are significantly higher in patients with Type 2 Diabetes (T2D) compared to those without.
In patients with Coronary Artery Disease (CAD), suPAR mediates more than 50% of the association between T2D and adverse outcomes, including cardiovascular death and myocardial infarction.
Unlike high-sensitivity C-reactive protein (hs-CRP), suPAR acts as a critical independent mediator of the diabetic cardiovascular risk profile.
These findings suggest that chronic immune activation, rather than just acute-phase inflammation, drives the poor prognosis seen in diabetic patients with heart disease.